- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01787149
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis
Study Overview
Detailed Description
The objectives of the study are to evaluate the efficacy and safety of ENIA11 in combination with DMARDs versus DMARDs alone in patients with rheumatoid arthritis.
This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in combination with DMARDs versus DMARDs alone in patients with rheumatoid arthritis.
The study period for each patient will be 28 weeks, during which the patient will undergo screening for up to 14 days, followed by treatment of 24 weeks and follow-up period of 2 weeks. Each patient will be required to make a total of 9 visits.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
Taipei, Taiwan
- Far Eastern Memorial Hospital
-
Taipei, Taiwan
- Cheng Hsin General Hospital
-
Taipei, Taiwan
- Taipei City Hospital
-
Taipei, Taiwan
- Cathay General Hospital
-
Taipei, Taiwan
- Mackay Memorial Hospital Institutional
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged ≥ 20 years old;
- Patient meet ACR criteria for rheumatoid arthritis over 6 month duration;
- Patient with active disease at the time of screening as defined by six or more swollen joints and six or more tender joints;
Presence of at least one of the following criteria:
- Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/h,
- C-Reactive Protein (CRP) ≥ 10 mg/L,
- RA functional class I, II, or III;
- Patients have been received stable doses of permitted DMARDs (methotrexate, hydroxychloroquine, sulfasalazine, azathioprine, and leflunomide) for at least 8 weeks prior enrollment.
- Patient is willing and able to comply with study procedures and sign informed consent.
Exclusion Criteria:
- Active autoimmune disease (other than RA) requiring immunosuppressive therapy;
- In the opinion of the investigator, the patient shows persistent signs of immunosuppression;
- Known hypersensitivity to etanercept or ENIA11 or any of its components;
- Previous unsuccessful treatment with etanercept, anti-TNF monoclonal antibodies or a soluble TNF receptor (e.g., infliximab);
- Suspected or diagnosed pulmonary tuberculosis, or other chronic or current infectious disease at discretion of investigator;
- Patients who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, hematological, gastrointestinal or psychiatric disease as determined by the clinical judgment of the investigator;
- Patients with any of the following laboratory abnormalities: ALT/AST > 3 times ULN, creatinine > 2 mg/dl, WBC < 3,000/mm3, Hgb < 8.5 g/dL, platelet count < 100,000/mm3;
- Patients have received live attenuated vaccination program within 3 months or BCG vaccine within 12 months prior enrollment;
Female patient of childbearing potential who:
- is lactating; or
- has positive urine pregnancy test at Visit 1; or
- refuse to adopt reliable method of contraception during the study;
- Diagnosis of primary fibromyalgia or other joint inflammatory disease including but not limited to gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease;
- Known or suspected positive serology for human immunodeficiency, hepatitis B or C virus;
- Patient has received any investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of investigational product;
- Patient has history of substance abuse, drug addiction or alcoholism;
- Patient who have had participated in prior phase I/II clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
DMARDs alone
|
|
Experimental: ENIA11
ENIA11 25 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACR20 responder at last treatment visit
Time Frame: Week 24
|
The primary efficacy endpoint is defined as ACR20 responder at last treatment visit (Week 24).
|
Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hsiao-Yi Lin, PHD, Taipei Veterans General Hospital, Taiwan
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSHEN1201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Combination With DMARDs
-
Vanda PharmaceuticalsCompletedPharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With EthanolCanada
-
Jiangsu HengRui Medicine Co., Ltd.CompletedUsed to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)China
-
Ain Shams UniversityCompletedMore Effective Postoperative Analgesia After Modified Radical Mastectomy With Better Drug Combination | More Prolonged Duration of Postoperative Analgesia After Modified Radical Mastectomy With Better Drug CombinationEgypt
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitRecruitingHealthy | Pharmacokinetic | Drug CombinationThailand
-
Hoffmann-La RocheCompletedDrug Therapy, CombinationUnited Kingdom
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitCompletedHealthy | Pharmacokinetics | Drug CombinationThailand
-
Cairo UniversityEnrolling by invitationCombination of General Anesthesia to Spinal and Epidural TechniquesEgypt
-
University of HelsinkiSocial Insurance Institution, Finland; City of Lohja, Services for Aged People and other collaboratorsCompletedPolypharmacy | Inappropriate Prescribing | Drug Therapy, CombinationFinland
-
Johannes Gutenberg University MainzUnknownFocus of the Study is to Evaluate a New Developed Deep-learning Computer-aided Detection System in Combination With LCI for Colorectal Polyp DetectionGermany
Clinical Trials on DMARDs
-
PfizerCompletedRheumatoid ArthritisDenmark
-
Hoffmann-La RocheCompleted
-
University of CagliariUniversity of Turin, Italy; University Hospital, Udine, Italy; Azienda Sanitaria... and other collaboratorsUnknownArthritis, Psoriatic | Ultrasonography | Minimal Disease, ResidualItaly
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Liga Panamericana de Asociaciones de Reumatologia...RecruitingArthritis, Rheumatoid | Arthritis, Psoriatic | SpondyloarthritisArgentina
-
DNAlyticsCliniques universitaires Saint-Luc- Université Catholique de LouvainUnknown
-
Alliancells Bioscience Corporation LimitedUnknownRheumatoid ArthritisChina
-
Hoffmann-La RocheCompleted
-
Diakonhjemmet HospitalOslo University Hospital; University Hospital of North Norway; Helse Nord-Trøndelag... and other collaboratorsRecruitingImmune-related Adverse EventNorway